Financial Contrast: e.l.f. Beauty (NYSE:ELF) vs. Niagen Bioscience (NASDAQ:NAGE)

Niagen Bioscience (NASDAQ:NAGE – Get Free Report) and e.l.f. Beauty (NYSE:ELF – Get Free Report) are both consumer staples companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.

Insider & Institutional Ownership

15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 92.4% of e.l.f. Beauty shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by company insiders. Comparatively, 3.5% of e.l.f. Beauty shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Niagen Bioscience and e.l.f. Beauty, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Niagen Bioscience 0 1 4 1 3.00
e.l.f. Beauty 1 5 9 3 2.78

Niagen Bioscience currently has a consensus target price of $8.50, suggesting a potential upside of 319.75%. e.l.f. Beauty has a consensus target price of $118.88, suggesting a potential upside of 3.53%. Given Niagen Bioscience’s stronger consensus rating and higher possible upside, research analysts clearly believe Niagen Bioscience is more favorable than e.l.f. Beauty.

Earnings & Valuation

This table compares Niagen Bioscience and e.l.f. Beauty”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Niagen Bioscience $129.42 million 1.24 $17.38 million $0.12 16.88
e.l.f. Beauty $1.64 billion 4.15 $26.32 million $1.45 79.19

e.l.f. Beauty has higher revenue and earnings than Niagen Bioscience. Niagen Bioscience is trading at a lower price-to-earnings ratio than e.l.f. Beauty, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Niagen Bioscience has a beta of 2.12, indicating that its stock price is 112% more volatile than the S&P 500. Comparatively, e.l.f. Beauty has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.

Profitability

This table compares Niagen Bioscience and e.l.f. Beauty’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Niagen Bioscience 8.37% 10.18% 7.57%
e.l.f. Beauty 4.47% 16.40% 7.89%

Summary

e.l.f. Beauty beats Niagen Bioscience on 10 of the 15 factors compared between the two stocks.

About Niagen Bioscience

(Get Free Report)

Niagen Bioscience, Inc. develops and markets products based on nicotinamide riboside (NR), a form of vitamin B3 studied for its role in supporting the body’s production of NAD+. Its offerings include Tru Niagen, a consumer dietary supplement, and Niagen, a branded NR ingredient supplied to other businesses. The company also conducts and supports research on NR, NAD+ and healthy aging. It was formerly known as ChromaDex Corporation and adopted the Niagen Bioscience name in 2025. Niagen Bioscience serves consumers and commercial customers in the United States and international markets through online sales, retail and distribution channels.

About e.l.f. Beauty

(Get Free Report)

e.l.f. Beauty, Inc. is a beauty company that develops, markets and sells cosmetics and skin-care products. Its portfolio includes e.l.f. Cosmetics and e.l.f. SKIN, as well as brands such as Naturium, Well People and Keys Soulcare. Products include makeup, skin-care treatments and related beauty items. Founded in 2004, the company sells through its own websites and retail partners, including mass-market and specialty beauty stores. Its products are available in the United States and international markets.

Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.